• Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer

    We are hopeful that entrectinib will help us control many cases of ROS1+ lung cancer in both the body and the brain,” says Robert C. Doebele, MD, PhD.

  • P53 “master switch” remains top target in gene signaling network controlling cancer suppression

    “There are few things that are as relevant across cancer types as p53. Now the question is what is the best approach to harness it,” says senior author Joaquin Espinosa, PhD.

  • Today is Mesothelioma Awareness Day!

    Today is Mesothelioma Awareness Day, marked across the country by events raising awareness of the…

  • Rob Kinas hosts tennis-themed events to raise money for cancer research

    “We do not say no,” says Rob Kinas about his philosophy for events raising monies for American Cancer Society. Kinas recently visited the Jennifer Richer lab at CU Cancer Center to see how the ACS funds research by early-career investigators.

  • Help Rochford Lab reach fundraising goal for childhood cancer research

    September is childhood cancer awareness month. The Rochford lab is organizing a few different events…

Patient Care

“Nothing more I can ask for” – Personalized medicine ensures mom will see her kids grow up

For Sarah McRorie, the time after the birth of her daughter Sloane brought hugs, kisses, new challenges…

Read the rest of this entry

colon cancer cu cancer center

Research

Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer

We are hopeful that entrectinib will help us control many cases of ROS1+ lung cancer in both the body and the brain,” says Robert C. Doebele, MD, PhD.

Read the rest of this entry

Meet the Experts

A CONVERSATION WITH ROBERT GARCEA, MD

Cervical cancer is directly related to prior infection with human papillomavirus (HPV). Primarily due to PAP…

Read the rest of this entry